

Resources for Physicians:

- Rutgers-Global TB institute pocket card of LTBI treatment (Pediatric card update will be available in 2020)
- <https://www.cdc.gov/tb/publications/lbti/default.htm>
- <https://www.cdc.gov/tb/publications/lbti/lbiresources.htm>
- [https://www.aap.org/en-us/Documents/periodicity\\_schedule.pdf](https://www.aap.org/en-us/Documents/periodicity_schedule.pdf)
- Script to explain LTBI treatment from San Francisco Dept of Health: <https://www.sfcddcp.org/wp-content/uploads/2018/01/Sample-LTBI-Script.pdf>
- Completion documentation: <https://www.cdc.gov/tb/publications/lbti/appendix.htm>
- Medication tracker of 12 week regimen: [https://www.cdc.gov/tb/publications/pamphlets/LTBI\\_Medication\\_Tracker.pdf](https://www.cdc.gov/tb/publications/pamphlets/LTBI_Medication_Tracker.pdf)
- CDC TB personal stories: <https://www.cdc.gov/tb/topic/basics/personalstories.htm>

California Pediatric TB risk Assessment tool (below)

<b>LTBI testing is recommended if any of the boxes below are checked.</b>	
<input type="checkbox"/>	<b>Birth, travel, or residence</b> in a country with an elevated TB rate for at least 1 month <ul style="list-style-type: none"><li>• Includes any country other than the United States, Canada, Australia, New Zealand, or a country in western or northern Europe</li><li>• If resources require prioritization within this group, prioritize patients with at least one medical risk for progression (see the California Adult Tuberculosis Risk Assessment User Guide for this list).</li><li>• Interferon Gamma Release Assay is preferred over Tuberculin Skin Test for non-U.S.-born persons <math>\geq 2</math> years old</li></ul>
<input type="checkbox"/>	<b>Immunosuppression</b> , current or planned HIV infection, organ transplant recipient, treated with TNF-alpha antagonist (e.g., infliximab, etanercept, others), steroids (equivalent of prednisone $\geq 2$ mg/kg/day, or $\geq 15$ mg/day for $\geq 2$ weeks) or other immunosuppressive medication
<input type="checkbox"/>	<b>Close contact</b> to someone with infectious TB disease during lifetime
<b>Treat for LTBI if LTBI test result is positive and active TB disease is ruled out.</b>	

- None**; no TB testing is indicated at this time.

<https://www.cdph.ca.gov/Programs/CID/DCDC/CDPH%20Document%20Library/TBCB-CA-Pediatric-TB-Risk-Assessment.pdf>

Resources for Patients:

- [Testing for Tuberculosis:](https://www.cdc.gov/tb/publications/factsheets/testing/tb_testing.htm)  
[https://www.cdc.gov/tb/publications/factsheets/testing/tb\\_testing.htm](https://www.cdc.gov/tb/publications/factsheets/testing/tb_testing.htm)
- [12-Dose Regimen for Latent TB InfectionCdc-pdf:](https://www.cdc.gov/tb/publications/pamphlets/12DoseLTBITreatmentbrochure8.5x11.pdf)  
<https://www.cdc.gov/tb/publications/pamphlets/12DoseLTBITreatmentbrochure8.5x11.pdf>
- [Isoniazid-specific regimenCdc-pdf:](https://www.cdc.gov/tb/publications/pdf/INH_508.pdf) [https://www.cdc.gov/tb/publications/pdf/INH\\_508.pdf](https://www.cdc.gov/tb/publications/pdf/INH_508.pdf)
- [Rifampin-specific regimenCdc-pdf](https://www.cdc.gov/tb/publications/pdf/RIF_508.pdf) :[https://www.cdc.gov/tb/publications/pdf/RIF\\_508.pdf](https://www.cdc.gov/tb/publications/pdf/RIF_508.pdf)
- [What You Need to Know About Your Medicine for Latent Tuberculosis \(TB\) Infection – Isoniazid and RifapentineCdc-pdf:](https://www.cdc.gov/tb/publications/pdf/3HP_508.pdf) [https://www.cdc.gov/tb/publications/pdf/3HP\\_508.pdf](https://www.cdc.gov/tb/publications/pdf/3HP_508.pdf)
- [12-Dose Regimen for Latent TB Infection-Medication Tracker and Symptom ChecklistCdc-pdf:](https://www.cdc.gov/tb/publications/pamphlets/LTBI_Medication_Tracker.pdf)  
[https://www.cdc.gov/tb/publications/pamphlets/LTBI\\_Medication\\_Tracker.pdf](https://www.cdc.gov/tb/publications/pamphlets/LTBI_Medication_Tracker.pdf)
- <https://www.healthychildren.org/English/health-issues/conditions/chest-lungs/Pages/Tuberculosis.aspx>
- <https://www.nj.gov/health/hivstdtb/tb/faq.shtml>